Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.47 |
| ▸ | CTSK | P43235 | 14/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21442831 | 1.00 | CTSS (0.47) | CTSSCTSKCTSLCTSBAAK1 | |
| SCHEMBL21442772 | 0.83 | CTSS (0.44) | CTSSCTSKCTSLCTSB | |
| SCHEMBL20181217 | 0.83 | CTSS (0.44) | CTSSCTSKCTSLCTSB | |
| SCHEMBL20164194 | 0.83 | ALDH1A1 (0.42) | — | |
| SCHEMBL20181226 | 0.82 | AAK1 (0.55) | CTSSCTSKCTSLCTSBAAK1 | |
| SCHEMBL21442822 | 0.82 | CTSS (0.43) | CTSSCTSKCTSLCTSBAAK1 | |
| SCHEMBL20181458 | 0.82 | CTSS (0.43) | CTSSCTSKCTSLCTSBAAK1 | |
| SCHEMBL20181312 | 0.80 | AAK1 (0.44) | CTSSCTSKCTSLCTSBAAK1 | |
| SCHEMBL21442814 | 0.80 | AAK1 (0.44) | CTSSCTSKCTSLCTSBAAK1 | |
| SCHEMBL2061998 | 0.78 | KCNA5 (0.54) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310777-B1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | CTSS 237/4885CTSK 86/4885CTSL 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.